HNMC (7799) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 禾榮科

HNMC (7799) reported revenue of NT$2 million for Oct 2026, +42.2% year on year and +78.9% from the previous month. Revenue for Jan–Oct 2026 was NT$6.8 million (-1.6% year on year).

Revenue for Oct 2026 was a record high (previous high: Dec 2025, NT$2 million). →

In Oct 2026, it ranked No. 144 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Mar 2025 NT$229,000Apr 2025 NT$765,00025/04May 2025 NT$686,000Jun 2025 NT$328,000Jul 2025 NT$1.1 million25/07Aug 2025 NT$884,000Sep 2025 NT$1.5 millionOct 2025 NT$1.4 million25/10Nov 2025 NT$1.4 millionDec 2025 NT$2 millionJan 2026 NT$1.7 million26/01Feb 2026 NT$190,000Mar 2026 NT$1 millionMay 2026 NT$504,00026/05Aug 2026 NT$334,000Sep 2026 NT$1.1 millionOct 2026 NT$2 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$2 million+42.2%+78.9%
Sep 2026NT$1.1 million-27.0%+230.8%
Aug 2026NT$334,000-62.2%—
Jul 2026NT$0-100.0%—
Jun 2026NT$0-100.0%-100.0%
May 2026NT$504,000-26.5%—
Apr 2026NT$0-100.0%-100.0%
Mar 2026NT$1 million+349.3%+441.6%
Feb 2026NT$190,000—-88.6%
Jan 2026NT$1.7 million—-15.5%
Dec 2025NT$2 million—+38.9%
Nov 2025NT$1.4 million—+2.2%
Oct 2025NT$1.4 million—-8.2%
Sep 2025NT$1.5 million—+71.3%
Aug 2025NT$884,000—-21.1%
Jul 2025NT$1.1 million—+241.5%
Jun 2025NT$328,000—-52.2%
May 2025NT$686,000—-10.3%
Apr 2025NT$765,000—+234.1%
Mar 2025NT$229,000——
Feb 2025NT$0——
Jan 2025NT$0——
Dec 2024NT$0——
Nov 2024NT$0-100.0%—
Oct 2024NT$0——

Jan–Oct 2026 cumulative: NT$6.8 million (-1.6% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: HNMC vs PEC / HNMC vs Lotus Pharm / HNMC vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16